A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
A Randomized, Controlled, Double-blind, Double-dummy, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Beijing Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female who are at age 40~80 years with PD, consistent with the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria and who are being treated with stable regimens of DDCI+LD but experiencing motor fluctuations.
- Mini Mental State Examination (MMSE) ≥ 24 at Screening Visit.
- Hoehn and Yahr Stage I-IV when "on" at Screening Visit.
- At Screening, the participant has predictable "Off" periods.
- Able and willing to provide a written informed consent.
Exclusion Criteria:
- Diagnosed with atypical or secondary parkinsonism.
- History of narrow angle glaucoma、peptic ulcer disease or upper gastrointestinal hemorrhage.
- Had prior functional neurosurgical treatment for PD or if such procedure(s) are planned or anticipated during the study period.
- Nonresponsive to LD therapy.
- In the opinion of the clinical investigator, Subjects who should not participate in the study.
- Subjects who are allergic to the investigational drug to be used in this study.
- Pregnant or breastfeeding.
- Participants who have previously participated in an HRG2010 study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo
|
Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally. |
|
Active Comparator: Sustained-release Carbidopa/Levodopa and HRG2010 placebo
|
Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in "Off" time at Week 21
Time Frame: Last three days collected at the end of treatment period, at Week 21
|
Last three days collected at the end of treatment period, at Week 21
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline in "On" Time Without Troublesome Dyskinesia at Week 21
Time Frame: Last three days collected at the end of treatment period, at Week 21
|
Last three days collected at the end of treatment period, at Week 21
|
|
Change from baseline in the Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at Week 21
Time Frame: Week 21
|
Week 21
|
|
Change from baseline in the 39-item Parkinson's Disease Questionnaire (PDQ-39) at Week 21
Time Frame: Week 21
|
Week 21
|
|
Adverse events
Time Frame: Week 23
|
Week 23
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Synucleinopathies
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurodegenerative Diseases
- Movement Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Parkinson Disease
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Amines
- Amino Acids
- Catechols
- Phenols
- Benzene Derivatives
- Phenylalanine
- Amino Acids, Aromatic
- Amino Acids, Cyclic
- Catecholamines
- Dihydroxyphenylalanine
- Tyrosine
- Levodopa
Other Study ID Numbers
Other Study ID Numbers
- HRG2010-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.